UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Annals of oncology, 2018-12, Vol.29 (12), p.2371-2378

2018

Volltextzugriff (PDF)

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma

Annals of oncology, 2015-12, Vol.26 (12), p.2457-2463

2015

Volltextzugriff (PDF)

Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

Annals of oncology, 2018-10, Vol.29, p.viii303-viii303

2018

Volltextzugriff (PDF)

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

ESMO open, 2024-06, Vol.9 (6), p.103466, Article 103466

2024

Volltextzugriff (PDF)

26 Patient Selection Markers for Anti-angiogenic Agents in Metastatic Renal Cell Carcinoma: Dream or Reality?

European journal of cancer (1990), 2012-11, Vol.48, p.11-11

2012

Volltextzugriff (PDF)

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

Investigational new drugs, 2013-12, Vol.31 (6), p.1547-1558

2013

Volltextzugriff (PDF)

Clinical Trial Simulations From a Model‐Based Meta‐Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

CPT: pharmacometrics and systems pharmacology, 2016-05, Vol.5 (5), p.274-282

2016

Volltextzugriff (PDF)

906PD - Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses

Annals of oncology, 2019-10, Vol.30, p.v358-v359

2019

Volltextzugriff (PDF)

906PDPhase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses

Annals of oncology, 2019-10, Vol.30, p.v358-v359

2019

Volltextzugriff (PDF)

264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

ESMO open, 2024-05, Vol.9, p.103285, Article 103285

2024

Volltextzugriff (PDF)

863OAxitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27, p.vi449-vi449

2016

Volltextzugriff (PDF)

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation

European journal of cancer (1990), 2003-03, Vol.39 (5), p.675-683

2003

Volltextzugriff (PDF)

Novel Circulating Proteins, Single Nucleotide Polymorphisms (SNPS), and Molecular Tumor Markers as Potential Biomarkers of Sunitinib Efficacy in Treatment-Naïve Patients (PTS) with Advanced Renal Cell Carcinoma (RCC)

Annals of oncology, 2012-09, Vol.23, p.ix262

2012

Volltextzugriff (PDF)

Randomised Study of Axitinib (Axi) Plus Best Supportive Care (Bsc) Versus Placebo (Pbo) Plus Bsc in Patients with Advanced Hepatocellular Carcinoma (Hcc) Following Prior Antiangiogenic Therapy

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

LBA17RANDOMISED STUDY OF AXITINIB (AXI) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO (PBO) PLUS BSC IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING PRIOR ANTIANGIOGENIC THERAPY

Annals of oncology, 2014-09, Vol.25 (suppl_4)

2014

Volltextzugriff (PDF)

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours

European journal of cancer (1990), 2002-12, Vol.38 (18), p.2407-2415

2002

Volltextzugriff (PDF)

Ongoing phase I and II studies of novel anthracyclines

Cardiovascular toxicology, 2007-06, Vol.7 (2), p.75-79

2007

Volltextzugriff (PDF)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study

British journal of cancer, 2000-02, Vol.82 (4), p.767-771

2000

Volltextzugriff (PDF)

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody

British journal of cancer, 1995-10, Vol.72 (4), p.928-933

1995

Volltextzugriff (PDF)

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation

Cancer Immunology, Immunotherapy, 1997-07, Vol.44 (5), p.257-264

1997

Volltextzugriff (PDF)

Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.2572-2572

2008

Volltextzugriff (PDF)

Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies

European journal of cancer (1990), 1996-03, Vol.32 (3), p.498-505

1996

Volltextzugriff (PDF)

Phase I/II trial of nemorubicin hydrochloride in combination with cisplatin is supported by new preclinical evidences of its mechanism of action

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14116-14116

2006

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma

Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

26 Patient Selection Markers for Anti-angiogenic Agents in Metastatic Renal Cell Carcinoma: Dream or Reality?

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

Clinical Trial Simulations From a Model‐Based Meta‐Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

906PD - Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses

906PDPhase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses

Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses

264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

863OAxitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation

Novel Circulating Proteins, Single Nucleotide Polymorphisms (SNPS), and Molecular Tumor Markers as Potential Biomarkers of Sunitinib Efficacy in Treatment-Naïve Patients (PTS) with Advanced Renal Cell Carcinoma (RCC)

Randomised Study of Axitinib (Axi) Plus Best Supportive Care (Bsc) Versus Placebo (Pbo) Plus Bsc in Patients with Advanced Hepatocellular Carcinoma (Hcc) Following Prior Antiangiogenic Therapy

LBA17RANDOMISED STUDY OF AXITINIB (AXI) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO (PBO) PLUS BSC IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING PRIOR ANTIANGIOGENIC THERAPY

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours

Ongoing phase I and II studies of novel anthracyclines

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation

Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)

Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies

Phase I/II trial of nemorubicin hydrochloride in combination with cisplatin is supported by new preclinical evidences of its mechanism of action

Suchergebnisse filtern